Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines. [Eine einarmige, offene, multizentrische Phase-II-Studie zum Nachweis der Wirksamkeit und Sicherheit von BIBW 2992 (Afatinib) in Kombination mit Vinorelbin zur Behandlung von Patientinnen mit metastasierendem Brustkrebs mit intermediärer HER2-Expression (HER2 2+ in der Immunhistochemie, Fluoreszenz in situ Hybridisierung (FISH) negativ) nach Versagen der Erstbehandlung der metastasierenden Erkrankung und Vorbehandlung mit Anthrazyklinen].

Next Previous
X
Search
Trial Profile

Single-arm, Open-label, Multicentre Phase II Study Evaluating the Efficacy and Safety of BIBW 2992 (Afatinib) in Combination With Vinorelbine for the Treatment of Patients With Metastatic Breast Cancer With Intermediate HER2 Expression (HER2 2+ by Immunohistochemistry, Fluorescence In-situ Hybridisation (FISH) Negative) After Failure of First-line Therapy in the Metastatic Setting and Having Been Pre-treated With Anthracyclines. [Eine einarmige, offene, multizentrische Phase-II-Studie zum Nachweis der Wirksamkeit und Sicherheit von BIBW 2992 (Afatinib) in Kombination mit Vinorelbin zur Behandlung von Patientinnen mit metastasierendem Brustkrebs mit intermediärer HER2-Expression (HER2 2+ in der Immunhistochemie, Fluoreszenz in situ Hybridisierung (FISH) negativ) nach Versagen der Erstbehandlung der metastasierenden Erkrankung und Vorbehandlung mit Anthrazyklinen].

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Vinorelbine
  • Indications Advanced breast cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 17 Oct 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 06 May 2012 New source identified and integrated (EudraCT2011-001765-41; European Clinical Trials Database).
    • 27 Apr 2012 Actual initiation date (Apr 2012) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top